View this email in your browser

TrialStat News for April 2020

To our clients, partners, and industry friends,

There is no doubt that we are in troubled times with COVID-19 dominating every aspect of our lives. This pandemic is prompting the clinical research sector to rapidly reinvent itself as we work to design and launch trials not only for a vaccine but other therapeutic treatment candidates, supportive medical devices and diagnostics, all while in the middle of a very challenging environment that is constantly evolving.

TrialStat Clients Begin First SARS-CoV-2 Studies
We are excited to announce the commencement of the first of many COVID-19 clinical studies using the TrialStat platform. These therapeutic trials will run in North America and take advantage of our multilingual EDC platform, randomization module, coding, and many more integrated features. Supporting our clients need for remote monitoring, TrialStat's EDC platform allows for the designation of non-clinical questions and forms with the ability to upload redacted PDF source documentation for remote review.

We are receiving many queries about how our services and solutions can best support new research projects or assist in improving ongoing clinical operations as many studies flex toward a more virtual and risk-based approach. We welcome the opportunity to talk to you about how our technology solutions enable teams to easily navigate their eClinical and data management requirements during this challenging time.

globe with mask in hands

We have seen an exceptional response from research teams to the challenge of COVID-19. Below is a roundup of some of the latest industry news that might be of interest to you. If you are working on something that would be of interest to our readers, we would love to hear about it so we can share it with our subscribers!

Upcoming Webinar Series - Leveraging EDC Technology For New and Ongoing Trials During Pandemic Mitigation Measures

We are planning a series of webinars focused on specific topics related to Electronic Data Capture, Data Management, Imaging Management, Machine Learning, eConsent, Virtual Trials and how these technologies can be leveraged during pandemic mitigation measures and beyond. Our team is in the process of finalizing topics and schedules, which we will share with you in the coming days.

As always, we wish you health and safety during this challenging time and look forward to the day of when we can all meet again in person to celebrate the successes that I know our industry will have in the fight against this virus.

Chris Hamelin
Business Unit Head
TrialStat Solutions Inc.

Hemarina offers its oxygen carrier molecule to fight the COVID-19 pandemic

“Hemarina, a French biotech company, could come to the help of doctors fighting the coronavirus. The company has developed a molecule derived from marine worms, which could help people seriously affected by the COVID-19, who do not have access to respirators. The molecule called M101, binds 40 times more oxygen than human hemoglobin, and thus could be helpful for people with respiratory problems.”

Continue Reading The Press Release

FDA authorizes Bodysphere 2-minute COVID-19 test

“Bodysphere announced today that it has begun distributing its 2-minute testing kit for diagnosing COVID-19 after receiving FDA emergency use authorization (EUA).

The Los Angeles-based company’s two-minute testing kit uses antibodies in blood to test for current or past infection with a 91% clinical specificity rate and a 99% clinical sensitivity rate, according to a news release. The test delivers results on-site in as fast as two minutes.”

Continue Reading Article

VCU doctor leading clinical trial on drug to treat COVID-19 encouraged by initial results

“RICHMOND, Va. (WRIC) — VCU Health is in the middle of conducting clinical trials for an experimental drug that could possibly treat COVID-19. Dr. Arun Sanyal, the doctor leading the trials, told 8News Tuesday that results are encouraging and it’s about improving how a patient feels, functions and survives.

Remdesivir, a drug used to experimentally treat Ebola in 2014, is now being studied at VCU Medical Center to possibly treat the novel coronavirus. VCU Health is one of the several medical facilities around the world testing the drug.”

Continue Reading Article

Additional News Stories

A New Paradigm in Data Management Technology

Learn More About TrialStat